Sight Sciences (SGHT) Projected to Post Quarterly Earnings on Thursday

Sight Sciences (NASDAQ:SGHT) is expected to issue its Q3 2025 results after the market closes on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.26) per share and revenue of $17.7440 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Thursday, November 6, 2025 at 4:30 PM ET.

Sight Sciences (NASDAQ:SGHT) last announced its quarterly earnings data on Wednesday, September 8th. The company reported ($0.81) EPS for the quarter. The company had revenue of $12.54 million during the quarter. Sight Sciences had a negative net margin of 64.23% and a negative return on equity of 59.38%. On average, analysts expect Sight Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Sight Sciences Stock Performance

Shares of SGHT opened at $4.98 on Wednesday. The company has a current ratio of 10.01, a quick ratio of 9.49 and a debt-to-equity ratio of 0.57. The stock has a market cap of $260.79 million, a P/E ratio of -5.19 and a beta of 2.46. The company has a 50-day moving average of $3.95 and a two-hundred day moving average of $3.78. Sight Sciences has a 12-month low of $2.03 and a 12-month high of $5.32.

Insider Transactions at Sight Sciences

In other news, insider Jeremy B. Hayden sold 9,731 shares of Sight Sciences stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $3.27, for a total transaction of $31,820.37. Following the completion of the sale, the insider directly owned 256,590 shares in the company, valued at $839,049.30. The trade was a 3.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Paul Badawi sold 24,441 shares of Sight Sciences stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $3.34, for a total transaction of $81,632.94. Following the sale, the chief executive officer owned 5,962,502 shares of the company’s stock, valued at approximately $19,914,756.68. This trade represents a 0.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 40,796 shares of company stock valued at $135,173. Insiders own 28.90% of the company’s stock.

Institutional Investors Weigh In On Sight Sciences

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Jane Street Group LLC acquired a new position in Sight Sciences during the second quarter worth approximately $148,000. Rhumbline Advisers increased its position in Sight Sciences by 9.6% during the second quarter. Rhumbline Advisers now owns 54,597 shares of the company’s stock worth $225,000 after purchasing an additional 4,800 shares during the last quarter. Geode Capital Management LLC increased its position in Sight Sciences by 5.5% during the second quarter. Geode Capital Management LLC now owns 845,776 shares of the company’s stock worth $3,494,000 after purchasing an additional 43,791 shares during the last quarter. Strs Ohio acquired a new position in Sight Sciences during the first quarter worth approximately $158,000. Finally, AQR Capital Management LLC acquired a new position in Sight Sciences during the first quarter worth approximately $128,000. 55.51% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Morgan Stanley lifted their target price on shares of Sight Sciences from $3.00 to $4.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 15th. Wall Street Zen upgraded shares of Sight Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, September 13th. Needham & Company LLC restated a “hold” rating on shares of Sight Sciences in a research report on Thursday, August 28th. Citigroup cut their target price on shares of Sight Sciences from $4.50 to $4.00 and set a “neutral” rating for the company in a research report on Tuesday, October 7th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Sight Sciences in a research report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Sight Sciences presently has an average rating of “Hold” and an average price target of $4.67.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.